* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and remains a leading cause of cancer-related mortality worldwide. Despite the success of tyrosine kinase inhibitors (TKIs) targeting oncogenic drivers such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS), acquired drug resistance inevitably emerges — most notably through secondary mutations (e.g., EGFR T790M/C797S, ALK G1202R), target protein overexpression, and bypass pathway activation. Proteolysis-targeting chimeras (PROTACs) offer a fundamentally different therapeutic strategy: instead of merely inhibiting the catalytic activity of an oncogenic protein, PROTACs hijack the ubiquitin-proteasome system (UPS) to induce complete, event-driven degradation of the target. This degradation-based mechanism eliminates both enzymatic and scaffolding functions of the target protein, providing a compelling solution to mutation-driven resistance, undruggable targets, and tumor heterogeneity in NSCLC.
BOC Sciences provides a fully integrated PROTAC discovery and development platform tailored to NSCLC targets. Our services span from target feasibility assessment and ligand design through PROTAC linker optimization, focused library synthesis, in vitro degradation profiling in NSCLC-relevant cell models, ternary complex characterization, and in vivo pharmacodynamic (PD) evaluation. Whether your program is focused on EGFR-resistant mutants, KRAS-driven lung adenocarcinoma, ALK-fusion-positive NSCLC, or emerging targets such as CD26, BRD4, or MET, we deliver chemistry-biology-integrated solutions that generate actionable data for each stage of your discovery pipeline.
Services
BOC Sciences' PROTAC Design and Development Services for NSCLC Targets
Target Protein Ligand Design and Optimization for NSCLC Oncoproteins
The foundation of any PROTAC program is a high-quality target protein ligand that provides sufficient binding affinity, appropriate exit vector geometry, and compatibility with linker conjugation without abolishing target engagement. BOC Sciences supports ligand design for target proteins across the full spectrum of NSCLC-relevant oncoproteins.
Structure-based ligand design for kinase targets: leveraging co-crystal structures and molecular docking to identify or optimize ATP-competitive, allosteric, or type-II ligands against EGFR, ALK, KRAS, MET, BRAF, ROS1, RET, and NTRK variants with suitable solvent-exposed exit vectors
Ligand design for non-kinase NSCLC targets: development of small-molecule or peptide-based ligands for BRD4, CDK4/6, BCL-xL, and transcription factors using virtual screening, fragment-based approaches, and structure-guided optimization
Mutant-selective ligand engineering: design of ligands that preferentially bind EGFR T790M, EGFR C797S, ALK G1202R, or KRAS G12C/G12D mutant proteins while sparing wild-type counterparts, enabling tumor-selective degradation
Ligand binding validation: confirmation of target engagement through surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), thermal shift assays, and cellular target engagement readouts
The choice of E3 ligase recruiter is a critical determinant of PROTAC degradation efficiency, selectivity, ternary complex cooperativity, and tissue-specific activity. BOC Sciences provides comprehensive E3 ligase ligand design and selection services covering the major ligase systems relevant to NSCLC.
VHL-based PROTAC development: design of von Hippel-Lindau (VHL)-recruiting PROTACs using VHL ligand derivatives with optimized linker attachment points; VHL-based degraders often exhibit favorable selectivity profiles and are well-suited for targets with moderate-to-high expression in NSCLC
CRBN-based PROTAC development: cereblon (CRBN)-recruiting strategies using pomalidomide, lenalidomide, and next-generation cereblon-modulating ligands; CRBN-based PROTACs are the most widely explored and offer the advantage of smaller recruiter molecular weight
IAP-based PROTAC development: inhibitor of apoptosis protein (IAP)-recruiting designs using LCL161-derived or related IAP antagonist ligands, particularly relevant for NSCLC settings where IAPs are overexpressed
MDM2-based PROTAC development: murine double minute 2 (MDM2)-recruiting PROTACs that co-opt the p53 regulatory axis; of special interest for NSCLC tumors retaining wild-type p53
Parallel recruiter screening: systematic comparison of VHL, CRBN, IAP, and MDM2-based PROTACs against the same target-ligand pair to identify the recruiter that maximizes degradation efficiency and minimizes off-target effects
Linker Design and Optimization for NSCLC PROTACs
Linker composition, length, rigidity, and attachment chemistry profoundly influence PROTAC ternary complex formation, cellular permeability, metabolic stability, and degradation cooperativity. BOC Sciences provides a full suite of linker design and optimization services tailored to the physicochemical demands of NSCLC targets.
PEG linker design: polyethylene glycol-based linkers offering flexibility, improved aqueous solubility, and tunable length for optimizing ternary complex geometry
Alkyl linker design: hydrophobic alkyl chain linkers that reduce the polar surface area and may enhance membrane permeability for PROTACs targeting intracellular NSCLC oncoproteins
Rigid linker design: incorporation of alkynes, piperazines, or aromatic spacers to pre-organize the ternary complex and reduce entropic penalties upon target-E3 ligase recruitment
Cleavable linker design: stimulus-responsive (e.g., hypoxia-sensitive, glutathione-sensitive) linkers for tumor microenvironment-activated PROTAC release in NSCLC
Heterocyclic linker design: heterocycle-containing linkers that modulate rigidity, polarity, and metabolic stability while providing additional hydrogen-bonding opportunities
Click chemistry linker assembly: copper-catalyzed or strain-promoted azide-alkyne cycloaddition strategies for modular, high-throughput PROTAC linker exploration
PROTAC Synthesis, Purification, and Characterization
PROTAC molecules — typically with molecular weights of 700–1,200 Da — present unique synthetic challenges due to their multi-component architecture and the need for high purity to support reliable biological interpretation. BOC Sciences offers dedicated custom PROTAC synthesis services with rigorous quality control.
Multi-gram synthesis: scalable synthetic routes for target protein ligand, E3 ligase recruiter, and linker intermediates, supporting both hit exploration and lead optimization quantities
Convergent assembly: late-stage conjugation strategies that maximize synthetic efficiency and enable rapid analog generation through modular building-block interchange
Negative control synthesis: preparation of PROTAC diastereomer negative controls, warhead-only controls, and E3-ligand-only controls essential for rigorous data interpretation
Analytical characterization: high-resolution mass spectrometry (HRMS), nuclear magnetic resonance (NMR), and high-performance liquid chromatography (HPLC) purity assessment for every compound delivered
Scale-up production: transition from milligram discovery quantities to gram-scale batches for advanced in vivo studies, with process optimization to maintain purity and yield
NSCLC Cell-Based Potency and Selectivity Profiling
Degradation potency and selectivity must be evaluated in disease-relevant cellular contexts. BOC Sciences maintains a panel of well-characterized NSCLC cell lines representing major molecular subtypes and resistance genotypes for PROTAC in vitro evaluation.
EGFR-mutant NSCLC models: profiling in HCC827 (EGFR del19), H1975 (EGFR L858R/T790M), and isogenic cell panels expressing single, double, or triple EGFR mutants including C797S
KRAS-mutant NSCLC models: evaluation in H358 (KRAS G12C), A549 (KRAS G12S), H441 (KRAS G12V), and H23 (KRAS G12C) cell lines
ALK-fusion models: testing in H3122 and H2228 (EML4-ALK variant 1 and variant 3) cells, including engineered lines expressing ALK resistance mutations
Quantitative degradation metrics: determination of DC50 (half-maximal degradation concentration), Dmax (maximal degradation extent), degradation rate (kdeg), and hook-effect characterization through Western blot, capillary-based automated immunoassay, and quantitative mass spectrometry
Selectivity evaluation: global proteomics analysis to assess degradation selectivity across the proteome, together with off-target evaluation against closely related kinase family members
In Vivo Exposure and Pharmacodynamic Evaluation
Translating in vitro degradation potency into meaningful in vivo target engagement requires careful pharmacokinetic (PK) and pharmacodynamic characterization. BOC Sciences supports PROTAC in vivo evaluation in NSCLC-relevant animal models.
PK evaluation: determination of oral bioavailability, plasma clearance, volume of distribution, half-life, and tissue distribution in rodent models, with attention to the disproportionately low plasma exposure common to PROTAC molecules
PD evaluation: measurement of target protein degradation kinetics in tumor xenograft tissue, correlating tumor drug exposure with degradation depth (Dmax) and duration
NSCLC xenograft and syngeneic models: efficacy studies in subcutaneous and orthotopic NSCLC xenografts (H1975, HCC827, A549, H3122) and immunocompetent models where tumor microenvironment contributions are relevant
Pharmacodynamic biomarker analysis: quantification of target protein levels, downstream pathway markers (e.g., phospho-ERK, phospho-AKT, cleaved PARP), and tumor proliferation/apoptosis indices in treated tumors
Toxicity evaluation: assessment of body weight changes, hematological parameters, and organ histopathology to characterize the therapeutic window of NSCLC PROTAC candidates
Target selection should be guided by genetic context, protein dependency, available ligandability, subcellular localization, E3 ligase compatibility, and the ability to measure degradation-driven biology. Our platform supports established NSCLC drivers as well as emerging dependencies that require chemical validation.
EGFR-Mutant and EGFR-Inhibitor-Resistant Targets
Our EGFR-targeting PROTAC programs can investigate activating variants, resistance-associated substitutions, compound mutations, and mutant-over-wild-type selectivity. Design strategies may use ATP-site, allosteric, covalent, or reversible-covalent recognition elements, followed by systematic comparison of E3 recruiters and linker geometry.
Exon 19 deletion and L858R activating variants
T790M and C797S-associated resistance contexts
Compound-mutant and heterogeneous cell model panels
Wild-type EGFR degradation and signaling controls
KRAS-Mutant and RAS–MAPK Pathway Targets
Our KRAS-targeting PROTAC capabilities support mutation-selective and broader RAS-pathway research. Programs may focus on direct KRAS degradation, removal of scaffold or signaling dependencies, and evaluation of downstream pathway collapse across RAF-MEK-ERK and PI3K-AKT signaling.
KRAS G12C, G12D, and other ligand-accessible variants
RAS-binding, membrane-localization, and pathway-dependency studies
RAF, MEK, ERK, SHP2, SOS1, and FAK-associated strategies
Adaptive feedback and pathway reactivation profiling
ALK, ROS1, RET, and NTRK Fusion Targets
Fusion oncoproteins may retain kinase activity while acquiring resistance substitutions or maintaining non-catalytic signaling functions. Through our ALK-targeting PROTAC platform, we evaluate fusion-selective degradation, solvent-front mutations, gatekeeper substitutions, E3 ligase compatibility, and downstream pathway suppression.
EML4-ALK fusion variants and resistant kinase-domain mutants
ROS1, RET, and NTRK fusion protein feasibility assessment
Fusion-partner and subcellular-localization considerations
Comparator studies against kinase inhibition alone
MET, HER2, BRAF, and PI3K–AKT Pathway Targets
Amplification, exon skipping, mutation, and bypass activation can create alternative survival routes in NSCLC. BOC Sciences supports MET, HER2, BRAF, and PI3K-targeting PROTAC development with target-specific ligand design, isoform selectivity assessment, downstream signaling analysis, and resistance-context modeling.
MET amplification, exon 14 skipping, and bypass signaling
HER2 mutation or amplification-associated dependencies
BRAF and MAPK pathway activation states
PI3K-AKT-mTOR signaling and feedback adaptation
Transcriptional and Epigenetic Dependencies
NSCLC cells may depend on transcription factors, chromatin readers, histone-modifying enzymes, or lineage-specific regulatory complexes that are incompletely addressed by conventional inhibitors. Degradation probes can help separate catalytic from scaffolding functions and reveal rapid transcriptional consequences.
BET family and BRD4-associated transcriptional programs
HDAC, CDK, and chromatin-regulatory dependencies
Lineage-survival and plasticity-associated transcription factors
Proteomic and transcriptomic response mapping
Cell-Cycle, Apoptosis, and Adaptive Resistance Targets
Degraders can be used to probe cell-cycle checkpoints, anti-apoptotic dependencies, DNA damage response proteins, and adaptive survival nodes. These targets are particularly relevant when the primary driver remains only partially suppressible or when combination strategies require a mechanistically defined sensitizer.
PLK1, CDKs, and mitotic checkpoint regulators
BCL-xL, MCL-1, and apoptosis-control proteins
ATR, PARP, WEE1, and DNA damage response pathways
Resistance-associated kinases, phosphatases, and scaffold proteins
Have You Encountered Following Challenges in NSCLC PROTAC Development?
Difficulty achieving mutant-selective EGFR degradation without affecting wild-type EGFR in normal tissues
Poor cellular permeability of PROTAC molecules in NSCLC cell lines despite potent biochemical degradation
Hook-effect limitations at higher concentrations that narrow the usable concentration range for in vivo studies
Inconsistent degradation across NSCLC models with different genetic backgrounds or pathway activation states
Insufficient oral bioavailability or rapid clearance limiting in vivo target engagement
Difficulty distinguishing on-target degradation from off-target cytotoxicity in proliferation-based assays
Tell Us Your Challenge
Contact us to discuss how we can help you overcome these hurdles
Our Solutions for NSCLC-Specific PROTAC Development Challenges
Developing PROTACs for NSCLC targets requires more than generic degrader chemistry — it demands an integrated understanding of tumor biology, resistance mechanisms, drug metabolism and pharmacokinetics (DMPK), and the unique physicochemical properties of heterobifunctional degraders. BOC Sciences provides targeted solutions for the most persistent challenges encountered in NSCLC PROTAC programs.
Addressing Tumor Selectivity and Minimizing Systemic On-Target Toxicity
Many NSCLC targets — EGFR, ALK, MET, CDK4/6 — also serve essential physiological functions in normal tissues. Our solution combines mutant-selective ligand design, recruiter selection biased toward E3 ligases differentially expressed in tumor tissue, and tumor-microenvironment-responsive linker strategies. We evaluate degradation selectivity in panels of NSCLC versus normal lung epithelial and other tissue-relevant cell lines, quantifying selectivity indices that guide prioritization of candidates with the widest tumor-to-normal degradation windows.
Balancing PROTAC Molecular Properties for Oral Bioavailability
PROTACs typically violate Lipinski's Rule of Five, presenting molecular weights of 700–1,200 Da and high polar surface areas that limit passive membrane permeability. We address this through systematic modulation of linker polarity, intramolecular hydrogen bond (IMHB) engineering to shield polar groups, and computational prediction of in silico physicochemical properties using ADMET prediction tools. For programs requiring oral exposure, we apply property-based design filters early in the hit-to-lead process to avoid late-stage PK attrition.
Engineering PROTACs Against Resistance-Conferring Target Mutations
NSCLC tumors under selective pressure from targeted therapies frequently acquire mutations in the drug-binding site that abrogate ligand binding. Our solution is to identify ligand-binding sites or allosteric pockets distant from the known mutational hotspots, or to employ reversible covalent warheads that retain binding to mutated cysteine or lysine residues. We also design parallel PROTAC series with distinct ligand chemotypes to ensure that at least one degrader retains activity against each clinically relevant mutant variant.
Overcoming Poor Solubility and Cellular Permeability
Poor aqueous solubility and limited cellular permeability are among the most common reasons PROTAC programs stall at the cell-based validation stage. We address solubility through co-solvent screening, amorphous solid dispersion formulation, and structural modifications that disrupt crystal packing. Permeability is improved through linker polarity reduction, N-methylation of solvent-exposed amides, and IMHB stabilization. Compounds are ranked by permeability–solubility composite scores before advancing to cellular degradation assays.
Workflow
End-to-End Workflow for NSCLC PROTAC Development
01
Target and Disease-Model Definition
Define the NSCLC genotype, target dependency, resistance mechanism, comparator models, measurable degradation endpoints, and project success criteria. Available structural data, ligands, cell lines, and reference compounds are reviewed before chemistry begins.
02
Ligand, Recruiter, and Linker Strategy Design
Select target-binding ligands, identify suitable exit vectors, compare E3 ligase recruiters, and design a focused linker matrix. Computational modeling and structural information are used to prioritize geometries with a higher probability of productive ternary complex formation.
03
Focused Library Synthesis and Compound Characterization
Synthesize a hypothesis-driven set that varies one or more key parameters, including linker length, rigidity, polarity, recruiter class, warhead attachment site, or stereochemistry. Compounds are isolated and structurally characterized before screening.
04
Biophysical and Biochemical Degradation Assessment
Confirm binary binding and evaluate ternary complex formation using methods appropriate to the target system. Our PROTAC ternary complex assays can be combined with ubiquitination and cell-free degradation studies to identify productive molecular interactions.
05
NSCLC Cell-Based Screening and Mechanism Validation
Measure concentration- and time-dependent target loss in mutation-matched NSCLC cells. Proteasome inhibition, neddylation inhibition, ligand competition, E3 ligase perturbation, and inactive controls are used to establish the intended degradation mechanism.
06
Lead Optimization and Selectivity Profiling
Integrate DC50, Dmax, degradation kinetics, cellular phenotype, permeability, solubility, metabolic stability, and proteomic selectivity. New analogs are designed around the experimentally identified bottleneck rather than potency alone.
07
In Vivo Proof-of-Concept Evaluation
Evaluate exposure, tumor distribution, target degradation, pathway modulation, and dose-time relationships in a fit-for-purpose research model. Sampling schedules are selected to capture both maximal degradation and protein recovery.
08
Data Integration and Next-Round Design
Build an integrated structure-degradation-property map, rank compounds against predefined criteria, identify unresolved risks, and recommend the next design cycle, model expansion, combination hypothesis, or target-validation experiment.
Advantages of PROTACs for Non-Small Cell Lung Cancer
Overcoming Resistance Mutations through Protein Degradation
PROTACs remove resistant proteins such as mutant EGFR instead of only blocking their active sites, providing another strategy for overcoming mutation-driven resistance.
Expanding Druggability to Scaffolds and Mutants
PROTACs can degrade scaffold proteins, fusion proteins, and selected mutants that are difficult to address with conventional inhibitors.
Event-Driven Degradation with Reduced Systemic Toxicity
PROTACs trigger repeated target degradation without continuous target binding, potentially achieving effective protein removal at lower exposure.
Degrading upstream proteins such as KRAS can suppress multiple signaling pathways and reduce compensatory pathway activation.
Applications
Applications of PROTACs in NSCLC Drug Discovery
Therapeutic Intervention for Resistant NSCLC Mutations
Post-osimertinib EGFR therapy: development of PROTACs that degrade EGFR T790M/C797S double- and triple-mutant proteins for NSCLC that has progressed on third-generation TKIs
ALK inhibitor-resistant disease: design of PROTACs targeting EML4-ALK G1202R and other solvent-front mutations that confer resistance to crizotinib, alectinib, and lorlatinib
KRAS-driven lung adenocarcinoma: degrader programs against KRAS G12C, G12D, and G12V mutants for patients whose tumors are refractory to covalent KRAS inhibitors
PROTAC Probes for Target Druggability Validation
Novel driver gene validation: rapid synthesis of PROTAC chemical probes against new candidate targets identified through NSCLC genomic screening (e.g., non-canonical fusion genes) to determine whether they represent functional dependency targets
Scaffold protein functional studies: development of degradation probes targeting scaffold proteins such as KSR1 to elucidate their non-catalytic functions in the MAPK pathway and assess their suitability as drug targets
Resistance mechanism mapping: targeted degradation of specific proteins to observe compensatory pathway activation, enabling construction of NSCLC drug-resistance network maps
Combination Therapy Enhancement in NSCLC
Chemotherapy sensitization: PROTACs degrading anti-apoptotic proteins such as BCL-xL in combination with platinum- or taxane-based chemotherapy to enhance apoptotic response in NSCLC cells
Immunotherapy combination: degradation of immunosuppressive proteins within the tumor microenvironment to improve response rates to PD-1/PD-L1 immune checkpoint inhibitors in NSCLC
Radiosensitization: targeted degradation of DNA damage repair pathway proteins such as poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia and Rad3-related protein (ATR) to enhance NSCLC cell sensitivity to radiotherapy
NSCLC Molecular Subtyping and Mechanistic Research
Signaling pathway dissection: use of PROTACs for rapid and reversible knockdown of key NSCLC nodal proteins (e.g., KRAS, EGFR) to resolve pathway hierarchies and crosstalk relationships
Lineage plasticity research: development of PROTACs degrading transcription factors implicated in NSCLC-to-small-cell lung cancer (SCLC) histological transformation, enabling investigation of phenotypic plasticity mechanisms
Tumor microenvironment studies: targeted degradation of key proteins in tumor-associated macrophages or cancer-associated fibroblasts to investigate stroma–tumor interactions influencing NSCLC progression
Accelerate Your NSCLC PROTAC Discovery with BOC Sciences
From mutant-selective EGFR degraders and pan-KRAS PROTACs to epigenetic-targeting and tumor-microenvironment-modulating degraders, BOC Sciences provides the integrated chemistry, biology, and DMPK capabilities needed to advance your NSCLC PROTAC program. Our interdisciplinary team combines deep knowledge of lung cancer biology with proven expertise in targeted protein degradation to deliver decision-ready data at every stage.
Client Success Stories in NSCLC PROTAC Development
Project Background
A pharmaceutical discovery team sought to develop an EGFR-targeting PROTAC capable of degrading the L858R/T790M/C797S triple-mutant EGFR protein found in osimertinib-resistant NSCLC, while sparing wild-type EGFR to minimize on-target toxicity in normal tissues. The client had a pyrimidine-based EGFR ligand with moderate affinity for the triple mutant (Kd ~120 nM) but needed a degrader design strategy that would achieve >80% degradation at sub-micromolar concentrations without affecting wild-type EGFR levels by more than 20%.
Our Support
We first performed molecular dynamics simulation of the ligand-bound EGFR T790M/C797S structure to identify solvent-exposed exit vectors suitable for linker attachment. Based on two viable exit vectors, we designed a 24-compound focused library spanning CRBN-based and VHL-based recruiters with PEG, alkyl, and semi-rigid piperazine-containing linkers of 8–18 atoms. Initial screening in Ba/F3 cells expressing EGFR L858R/T790M/C797S versus wild-type EGFR revealed that CRBN-based PROTACs with 12–14 atom PEG linkers achieved the best degradation selectivity window. We then synthesized 18 second-round analogs fine-tuning linker rigidity and recruiter attachment chemistry. The lead compound achieved DC50 = 48 nM and Dmax = 91% for the triple mutant, with less than 15% wild-type EGFR degradation at 1 μM — a selectivity index exceeding 20-fold. Downstream phospho-ERK suppression and apoptosis induction were confirmed in H1975-derived cell lines engineered to express the C797S mutation.
Client Testimonial
BOC Sciences transformed our initial ligand into a mutant-selective PROTAC series with clearly interpretable structure–degradation relationships. Their systematic approach to balancing degradation potency against wild-type selectivity gave us confidence to advance the program toward in vivo evaluation.
Project Background
A biotechnology company had identified a novel small-molecule ligand binding to the switch-II pocket of KRAS G12C with promising biochemical affinity (IC50 ~85 nM in nucleotide exchange assays) but observed no measurable KRAS degradation when conjugated to a CRBN recruiter via a simple alkyl linker in H358 NSCLC cells. The client needed to understand why the degrader was inactive and whether linker engineering could rescue productive ternary complex formation.
Our Support
We conducted a systematic diagnostic workflow: SPR confirmed that both the PROTAC–KRAS G12C and PROTAC–CRBN binary interactions were intact, but a ternary complex cooperativity assay revealed minimal cooperativity (α < 2), indicating that the linker was too short to accommodate simultaneous engagement of both proteins. Using protein structure modeling, we estimated the required linker span and designed 20 analogs with linker lengths from 14 to 26 atoms, incorporating PEG, alkyl-PEG hybrid, and semi-rigid motifs. Screening in H358 cells identified three PROTACs with DC50 values below 200 nM and Dmax > 75%. The best compound — a 20-atom alkyl-PEG hybrid linker with a rigid propargyl spacer near the KRAS ligand — achieved DC50 = 95 nM, Dmax = 88%, and sustained KRAS depletion beyond 48 hours. Global proteomics confirmed selectivity, with only two off-targets degraded by >50% at 10× DC50. The client received a comprehensive SAR map, the lead compound, and a clear path for in vivo PK/PD studies.
Client Testimonial
The BOC Sciences team diagnosed the ternary complex defect that was invisible to standard binding assays and rapidly identified linker geometries that restored productive KRAS degradation. Their mechanistic rigor saved us months of unguided linker exploration.
Why Us
Why Choose BOC Sciences for NSCLC PROTAC Programs?
Integrated NSCLC Biology and PROTAC Chemistry Expertise
Our team combines deep knowledge of NSCLC molecular pathology — including mutational landscapes, resistance mechanisms, and signaling network architecture — with hands-on PROTAC design and synthesis experience. This dual expertise ensures that degrader programs are grounded in both disease biology and practical medicinal chemistry from the outset.
Disease-Relevant Mutant and Resistance Model Coverage
We maintain a curated panel of NSCLC cell lines covering the major molecular subtypes — EGFR-mutant (del19, L858R, T790M, C797S), KRAS-mutant (G12C, G12V, G12S, G12D), ALK-fusion, MET exon 14-skipping, and BRAF V600E — enabling degradation profiling in the most translationally relevant cellular contexts.
Orthogonal Degradation and Mechanism Validation
We deploy multi-assay validation workflows combining Western blot, capillary immunoassay, targeted proteomics, global proteomics, ternary complex cooperativity measurement, and pathway-specific functional readouts. This orthogonal approach distinguishes genuine PROTAC-mediated degradation from assay artifacts or off-target cytotoxicity.
Iterative Design-Make-Test-Learn Optimization
NSCLC PROTAC programs benefit from rapid, data-driven iteration. Each design cycle integrates degradation potency, selectivity, permeability, metabolic stability, and ternary complex data to refine ligand choice, linker architecture, and recruiter selection. Clients receive clear SAR summaries after each cycle to guide decision-making.
Flexible Modular and End-to-End Service Models
Whether you need a single service module — such as linker optimization for an existing PROTAC series or cellular degradation profiling in NSCLC lines — or a fully integrated program from target concept to in vivo PD data, BOC Sciences adapts to your project stage, budget, and strategic objectives.
Decision-Focused Data Interpretation and Reporting
We deliver more than raw data. Every project concludes with an integrated report that contextualizes degradation results within NSCLC biology, identifies structure–activity trends, flags potential liabilities, and provides actionable recommendations for the next research phase — enabling confident, evidence-based program decisions.
PROTACs remove epidermal growth factor receptor (EGFR) proteins rather than continuously occupying the kinase active site. This mechanism can eliminate catalytic activity, scaffolding functions, and associated signaling complexes. For T790M, C797S, and compound mutations, degrader design may combine a mutant-preferring ligand with an appropriate E3 ligase recruiter and optimized linker. Mutant and wild-type EGFR should be compared through DC50, Dmax, degradation kinetics, protein recovery, and downstream signaling measurements to determine whether a useful selectivity window has been achieved.
Which NSCLC targets are suitable for PROTAC development?
Suitable targets generally have a defined disease dependency, an accessible binding ligand, a protein surface compatible with ternary complex formation, and measurable degradation-driven biology. Common NSCLC targets include EGFR, KRAS, ALK, MET, HER2, BRAF, PI3K, and BRD4. Programs may also address fusion proteins, scaffold proteins, anti-apoptotic factors, and adaptive resistance nodes. Feasibility assessment should consider subcellular localization, protein turnover, available lysines, E3 ligase expression, ligand exit vectors, and the availability of genetically matched cellular models.
What determines degrader selectivity in NSCLC cells?
Selectivity is created by the combined effects of target-ligand recognition, E3 ligase recruitment, linker geometry, ternary complex cooperativity, and cellular context. A mutant-selective warhead may reduce engagement of the wild-type protein, while recruiter selection can exploit differences in E3 ligase abundance or accessibility. Parallel testing in mutant NSCLC cells, wild-type control cells, and normal lung-related models is important. Proteomic profiling, ligand competition, proteasome inhibition, and inactive control compounds can further distinguish intended degradation from off-target protein loss or nonspecific cellular stress.
How are NSCLC PROTACs validated experimentally?
Reliable validation requires more than a cell-viability assay. BOC Sciences can combine concentration- and time-dependent protein measurements, DC50 and Dmax determination, ternary complex analysis, ubiquitination studies, and proteasome or neddylation inhibition experiments. Downstream markers such as phospho-ERK, phospho-AKT, cell-cycle proteins, and apoptosis signals can then connect target loss with biological response. Warhead-only controls, E3 ligand controls, inactive stereoisomers, and ligand competition studies help exclude simple inhibition, assay artifacts, and nonspecific cytotoxicity.
Why do NSCLC PROTACs show poor cellular permeability?
PROTACs often have high molecular weight, many hydrogen-bond donors and acceptors, and a large polar surface area, which can limit passive membrane transport. BOC Sciences can optimize permeability by adjusting PEG-to-alkyl balance, reducing exposed linker polarity, modifying amide content, introducing controlled rigidity, and encouraging intramolecular hydrogen bonding. Optimization should evaluate solubility, membrane permeability, intracellular exposure, metabolic stability, and degradation activity together. Improving only one property may weaken target binding, E3 recruitment, or productive ternary complex formation.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Overcoming Resistance Mutations through Protein Degradation
